Global Multiple Sclerosis Market By Types (Clinically isolated syndrome (CIS), Relapse-Remitting MS (RRMS), Primary Progressive MS (PPMS), Secondary Progressive MS (SPMS)), By Diagnosis (Blood Test, Spinal Tap, MRI , Evoked Potential Tests, Optical Coherence Tomography (OCT) Others)By Route of Administration(Subcutaneous, Oral, Intravenous) By Treatment (Corticosteroids, Disease-modifying therapies (DMTs) Plasma exchange (plasmapheresis) Injectable, Oral treatments, Infusions treatments, Physical Therapy, Others) By End Users( Hospitals, Speciality Clinics, Homecare, Others) By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
The severe demyelinating, inflammatory illness of the central nervous system (CNS) known as multiple sclerosis (MS) has become one of the leading causes of disability in young adults and is a significant socioeconomic issue globally. According to the MS International Federation, this illness affects roughly 2.5 million people globally. Although MS has a wide range of clinical manifestations, advanced biological therapeutics have made significant progress. There are significant difficulties in providing proper treatment and accessibility to therapies as MS is becoming more prevalent. The socioeconomic difficulties brought on by MS as a universal disease are highlighted across nations with developing economies, but they are also a crucial factor to take into account in industrialised nations with, on paper, better developed healthcare systems. Exposure to environmental changes, improved medical education on the condition, an increase in the availability of neurologists and magnetic resonance imaging (MRI) equipment worldwide, and widespread public awareness, including locally developed patient support groups and coordinated international advocacy groups, are additional factors causing multiple sclerosis awareness & treatments to become more prevalent globally. Furthermore, the multiple sclerosis market players are looking forward to mergers and acquisitions to launch and introduce advanced diagnosis and treatments for multiple sclerosis which in turn has contributed to the overall growth of global multiple sclerosis market.
In terms of revenue, global multiple sclerosis market was valued at US$ 23.89 Bn in 2021 growing at a CAGR of 3% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Multiple Sclerosis Market Revenue & Forecast, (US$ Million), 2015 – 2030
Diagnosis Outlook
Based on the diagnosis segment, the global multiple sclerosis market is segmented into blood test, spinal tap, MRI, evoked potential tests, others. Multiple sclerosis cannot be definitively diagnosed by a single test, making diagnosis challenging. Various neurological tests and MRIs are done to detect any damage or scarring of the myelin sheath (the layer surrounding nerves) in the brain and spinal cord to diagnose multiple sclerosis. Moreover, with advancements in various tests such as lumbar puncture, evoked potential tests, spinal test have made it slightly easier to detect various symptoms at an early stage for effective treatments. Thus, in the upcoming years with the incorporation of technology for its diagnosis, the global multiple sclerosis market is anticipated to rise exponentially.
Treatment Outlook
The treatments for multiple sclerosis are quite limited, but there are a wide range of treatment options that improved the long-term outcome in patients. Disease-modifying therapy (DMT) for the underlying immunological dysfunction and medicines to treat or manage symptoms are the two main components of MS treatment. For the treatment of acute relapses, corticosteroids have been prominently used. Corticosteroid pulse treatment clearly shortens the duration of acute relapses, but its long-term effect on disease course is less certain. Treatment of multiple sclerosis with long-term, low-dose corticosteroids has been studied for several decades and has not proved effective and thus stem cell therapy and advanced infusion therapies are being widely used for multiple sclerosis treatment. Furthermore, treatment of multiple sclerosis has widened to include a growing list of injectable disease-modifying agents and the recently introduced Fingolimod is the sole oral therapy available. Moreover, market players are investing into advanced treatments. For instance, Pipeline Therapeutics is set to commence the Phase Ib/IIa clinical trial of its lead programme, PIPE-307, to treat relapsing-remitting multiple sclerosis (RRMS) patients. Hence with advancements in treatments the global multiple sclerosis market is expected into boost during the forecast period 2022-2030.
Region Outlook
Based on the regions, North America accounted for the highest market share in the multiple sclerosis market in the year 2021. In a recent study, it was estimated that one million people in United States were currently suffering from multiple sclerosis wherein 85% are affected from relapsing-remitting MS that affects about 85% of all people with MS, although they may eventually transition to another form. Thus, to cater to the rising cases of multiple sclerosis, market players in North America are introducing advanced diagnosis and treatments. Moreover, the presence of the leading market players such as Novartis, Bayer, Pfizer in the North America region is contributing to the growth of the multiple sclerosis market.
Competitive Landscape
The report provides both, qualitative and quantitative research of global multiple sclerosis market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
A few of the key players operating in the global multiple sclerosis market are listed below:
- Acorda Therapeutics
- Bayer AG
- Berlex
- Biogen
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Pfizer Inc
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- TG Therapeutics, Inc.
- Other market participants
Global Multiple Sclerosis Market
By Types
- Clinically isolated syndrome (CIS)
- Relapse-remitting MS (RRMS)
- Primary progressive MS (PPMS)
- Secondary progressive MS (SPMS)
By Diagnosis
- Blood Test
- Spinal Tap
- MRI
- Evoked potential tests
- Optical coherence tomography (OCT)
- Others
By Route of Administration
- Subcutaneous
- Oral
- Intravenous
By Treatment
- Corticosteroids
- Disease-modifying therapies (DMTs)
- Plasma exchange (plasmapheresis)
- Injectables
- Oral treatments
- Infusions treatments
- Physical Therapy
- Others
By End User
- Hospitals
- Specialty Clinics
- Homecare
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 - 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Multiple Sclerosis Market
6.
Market
Synopsis:Â Multiple Sclerosis Market
7.
Multiple
Sclerosis Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Multiple Sclerosis Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Multiple Sclerosis Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Multiple Sclerosis
Market
8.
Global
Multiple Sclerosis Market Analysis and Forecasts, 2022 - 2030
8.1. Overview
8.1.1. Global Multiple Sclerosis Market Revenue (US$
Mn)
8.2. Global Multiple Sclerosis Market Revenue (US$
Mn) and Forecasts, By Type
8.2.1. Clinically isolated syndrome (CIS)
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 - 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 - 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 - 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 - 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 - 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 - 2030
8.2.2. Relapse-remitting MS (RRMS)
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 - 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 - 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 - 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 - 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 - 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 - 2030
8.2.3. Primary progressive MS (PPMS)
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.3.3.
Market
Forecast, 2022 - 2030
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2021
8.2.3.5.1.2. Market Forecast, 2022 - 2030
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2021
8.2.3.5.2.2. Market Forecast, 2022 - 2030
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2021
8.2.3.5.3.2. Market Forecast, 2022 - 2030
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2021
8.2.3.5.4.2. Market Forecast, 2022 - 2030
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2021
8.2.3.5.5.2. Market Forecast, 2022 - 2030
8.2.4. Secondary progressive MS (SPMS)
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.4.3.
Market
Forecast, 2022 - 2030
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2021
8.2.4.5.1.2. Market Forecast, 2022 - 2030
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2021
8.2.4.5.2.2. Market Forecast, 2022 - 2030
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2021
8.2.4.5.3.2. Market Forecast, 2022 - 2030
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2021
8.2.4.5.4.2. Market Forecast, 2022 - 2030
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2021
8.2.4.5.5.2. Market Forecast, 2022 - 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Type
9.
Global
Multiple Sclerosis Market Analysis and Forecasts, 2022 - 2030
9.1. Overview
9.2. Global Multiple Sclerosis Market Revenue (US$
Mn) and Forecasts, By Diagnosis
9.2.1. Blood Test
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 - 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 - 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 - 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 - 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 - 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 - 2030
9.2.2. Spinal Tap
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 - 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 - 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 - 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 - 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 - 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 - 2030
9.2.3. MRI scans
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.3.3.
Market
Forecast, 2022 - 2030
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2021
9.2.3.5.1.2. Market Forecast, 2022 - 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2021
9.2.3.5.2.2. Market Forecast, 2022 - 2030
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2021
9.2.3.5.3.2. Market Forecast, 2022 - 2030
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2021
9.2.3.5.4.2. Market Forecast, 2022 - 2030
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2021
9.2.3.5.5.2. Market Forecast, 2022 - 2030
9.2.4. Evoked potential tests
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.4.3.
Market
Forecast, 2022 - 2030
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2021
9.2.4.5.1.2. Market Forecast, 2022 - 2030
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2021
9.2.4.5.2.2. Market Forecast, 2022 - 2030
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2021
9.2.4.5.3.2. Market Forecast, 2022 - 2030
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2021
9.2.4.5.4.2. Market Forecast, 2022 - 2030
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2021
9.2.4.5.5.2. Market Forecast, 2022 - 2030
9.2.5. Optical coherence tomography (OCT)
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.5.3.
Market
Forecast, 2022 - 2030
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1. Market Estimation, 2015 - 2021
9.2.5.5.1.2. Market Forecast, 2022 - 2030
9.2.5.5.2.
Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2021
9.2.5.5.2.2. Market Forecast, 2022 - 2030
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2021
9.2.5.5.3.2. Market Forecast, 2022 - 2030
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2021
9.2.5.5.4.2. Market Forecast, 2022 - 2030
9.2.5.5.5.
Latin
America
9.2.5.5.5.1. Market Estimation, 2015 - 2021
9.2.5.5.5.2. Market Forecast, 2022 - 2030
9.2.6. Others
9.2.6.1.
Definition
9.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.6.3.
Market
Forecast, 2022 - 2030
9.2.6.4.
Compound
Annual Growth Rate (CAGR)
9.2.6.5.
Regional
Bifurcation
9.2.6.5.1.
North
America
9.2.6.5.1.1. Market Estimation, 2015 - 2021
9.2.6.5.1.2. Market Forecast, 2022 - 2030
9.2.6.5.2.
Europe
9.2.6.5.2.1. Market Estimation, 2015 - 2021
9.2.6.5.2.2. Market Forecast, 2022 - 2030
9.2.6.5.3.
Asia
Pacific
9.2.6.5.3.1. Market Estimation, 2015 - 2021
9.2.6.5.3.2. Market Forecast, 2022 - 2030
9.2.6.5.4.
Middle
East and Africa
9.2.6.5.4.1. Market Estimation, 2015 - 2021
9.2.6.5.4.2. Market Forecast, 2022 - 2030
9.2.6.5.5.
Latin
America
9.2.6.5.5.1. Market Estimation, 2015 - 2021
9.2.6.5.5.2. Market Forecast, 2022 - 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Diagnosis
10. Global Multiple Sclerosis Market Analysis
and Forecasts, 2022 - 2030
10.1. Overview
10.2. Global Multiple Sclerosis Market Revenue (US$
Mn) and Forecasts, By Route of Administration
10.2.1. Subcutaneous
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.1.3.
Market
Forecast, 2022 - 2030
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 - 2030
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 - 2030
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 - 2030
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 - 2030
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 - 2030
10.2.2. Oral
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.2.3.
Market
Forecast, 2022 - 2030
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 - 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 - 2030
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 - 2030
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 - 2030
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 - 2030
10.2.3. Intravenous
10.2.3.1.
Definition
10.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.3.3.
Market
Forecast, 2022 - 2030
10.2.3.4.
Compound
Annual Growth Rate (CAGR)
10.2.3.5.
Regional
Bifurcation
10.2.3.5.1.
North
America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 - 2030
10.2.3.5.2.
Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 - 2030
10.2.3.5.3.
Asia
Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 - 2030
10.2.3.5.4.
Middle
East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 - 2030
10.2.3.5.5.
Latin
America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 - 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Route of Administration
11. Global Multiple Sclerosis Market Analysis
and Forecasts, 2022 - 2030
11.1. Overview
11.2. Global Multiple Sclerosis Market Revenue (US$
Mn) and Forecasts, By Treatment
11.2.1. Corticosteroids
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.1.3.
Market
Forecast, 2022 - 2030
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2021
11.2.1.5.1.2. Market Forecast, 2022 - 2030
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2021
11.2.1.5.2.2. Market Forecast, 2022 - 2030
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2021
11.2.1.5.3.2. Market Forecast, 2022 - 2030
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2021
11.2.1.5.4.2. Market Forecast, 2022 - 2030
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2021
11.2.1.5.5.2. Market Forecast, 2022 - 2030
11.2.2. Disease-modifying therapies (DMTs)
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.2.3.
Market
Forecast, 2022 - 2030
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1.
North
America
11.2.2.5.1.1. Market Estimation, 2015 - 2021
11.2.2.5.1.2. Market Forecast, 2022 - 2030
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2021
11.2.2.5.2.2. Market Forecast, 2022 - 2030
11.2.2.5.3.
Asia
Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2021
11.2.2.5.3.2. Market Forecast, 2022 - 2030
11.2.2.5.4.
Middle
East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2021
11.2.2.5.4.2. Market Forecast, 2022 - 2030
11.2.2.5.5.
Latin
America
11.2.2.5.5.1. Market Estimation, 2015 - 2021
11.2.2.5.5.2. Market Forecast, 2022 - 2030
11.2.3. Plasma exchange (plasmapheresis)
11.2.3.1.
Definition
11.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.3.3.
Market
Forecast, 2022 - 2030
11.2.3.4.
Compound
Annual Growth Rate (CAGR)
11.2.3.5.
Regional
Bifurcation
11.2.3.5.1.
North
America
11.2.3.5.1.1. Market Estimation, 2015 - 2021
11.2.3.5.1.2. Market Forecast, 2022 - 2030
11.2.3.5.2.
Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2021
11.2.3.5.2.2. Market Forecast, 2022 - 2030
11.2.3.5.3.
Asia
Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2021
11.2.3.5.3.2. Market Forecast, 2022 - 2030
11.2.3.5.4.
Middle
East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2021
11.2.3.5.4.2. Market Forecast, 2022 - 2030
11.2.3.5.5.
Latin
America
11.2.3.5.5.1. Market Estimation, 2015 - 2021
11.2.3.5.5.2. Market Forecast, 2022 - 2030
11.2.4. Injectables
11.2.4.1.
Definition
11.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.4.3.
Market
Forecast, 2022 - 2030
11.2.4.4.
Compound
Annual Growth Rate (CAGR)
11.2.4.5.
Regional
Bifurcation
11.2.4.5.1.
North
America
11.2.4.5.1.1. Market Estimation, 2015 - 2021
11.2.4.5.1.2. Market Forecast, 2022 - 2030
11.2.4.5.2.
Europe
11.2.4.5.2.1. Market Estimation, 2015 - 2021
11.2.4.5.2.2. Market Forecast, 2022 - 2030
11.2.4.5.3.
Asia
Pacific
11.2.4.5.3.1. Market Estimation, 2015 - 2021
11.2.4.5.3.2. Market Forecast, 2022 - 2030
11.2.4.5.4.
Middle
East and Africa
11.2.4.5.4.1. Market Estimation, 2015 - 2021
11.2.4.5.4.2. Market Forecast, 2022 - 2030
11.2.4.5.5.
Latin
America
11.2.4.5.5.1. Market Estimation, 2015 - 2021
11.2.4.5.5.2. Market Forecast, 2022 - 2030
11.2.5. Oral Treatments
11.2.5.1.
Definition
11.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.5.3.
Market
Forecast, 2022 - 2030
11.2.5.4.
Compound
Annual Growth Rate (CAGR)
11.2.5.5.
Regional
Bifurcation
11.2.5.5.1.
North
America
11.2.5.5.1.1. Market Estimation, 2015 - 2021
11.2.5.5.1.2. Market Forecast, 2022 - 2030
11.2.5.5.2.
Europe
11.2.5.5.2.1. Market Estimation, 2015 - 2021
11.2.5.5.2.2. Market Forecast, 2022 - 2030
11.2.5.5.3.
Asia
Pacific
11.2.5.5.3.1. Market Estimation, 2015 - 2021
11.2.5.5.3.2. Market Forecast, 2022 - 2030
11.2.5.5.4.
Middle
East and Africa
11.2.5.5.4.1. Market Estimation, 2015 - 2021
11.2.5.5.4.2. Market Forecast, 2022 - 2030
11.2.5.5.5.
Latin
America
11.2.5.5.5.1. Market Estimation, 2015 - 2021
11.2.5.5.5.2. Market Forecast, 2022 - 2030
11.2.6. Infusions
11.2.6.1.
Definition
11.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.6.3.
Market
Forecast, 2022 - 2030
11.2.6.4.
Compound
Annual Growth Rate (CAGR)
11.2.6.5.
Regional
Bifurcation
11.2.6.5.1.
North
America
11.2.6.5.1.1. Market Estimation, 2015 - 2021
11.2.6.5.1.2. Market Forecast, 2022 - 2030
11.2.6.5.2.
Europe
11.2.6.5.2.1. Market Estimation, 2015 - 2021
11.2.6.5.2.2. Market Forecast, 2022 - 2030
11.2.6.5.3.
Asia
Pacific
11.2.6.5.3.1. Market Estimation, 2015 - 2021
11.2.6.5.3.2. Market Forecast, 2022 - 2030
11.2.6.5.4.
Middle
East and Africa
11.2.6.5.4.1. Market Estimation, 2015 - 2021
11.2.6.5.4.2. Market Forecast, 2022 - 2030
11.2.6.5.5.
Latin
America
11.2.6.5.5.1. Market Estimation, 2015 - 2021
11.2.6.5.5.2. Market Forecast, 2022 - 2030
11.2.7. Physical Therapy
11.2.7.1.
Definition
11.2.7.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.7.3.
Market
Forecast, 2022 - 2030
11.2.7.4.
Compound
Annual Growth Rate (CAGR)
11.2.7.5.
Regional
Bifurcation
11.2.7.5.1.
North
America
11.2.7.5.1.1. Market Estimation, 2015 - 2021
11.2.7.5.1.2. Market Forecast, 2022 - 2030
11.2.7.5.2.
Europe
11.2.7.5.2.1. Market Estimation, 2015 - 2021
11.2.7.5.2.2. Market Forecast, 2022 - 2030
11.2.7.5.3.
Asia
Pacific
11.2.7.5.3.1. Market Estimation, 2015 - 2021
11.2.7.5.3.2. Market Forecast, 2022 - 2030
11.2.7.5.4.
Middle
East and Africa
11.2.7.5.4.1. Market Estimation, 2015 - 2021
11.2.7.5.4.2. Market Forecast, 2022 - 2030
11.2.7.5.5.
Latin
America
11.2.7.5.5.1. Market Estimation, 2015 - 2021
11.2.7.5.5.2. Market Forecast, 2022 - 2030
11.2.8. Others
11.2.8.1.
Definition
11.2.8.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.8.3.
Market
Forecast, 2022 - 2030
11.2.8.4.
Compound
Annual Growth Rate (CAGR)
11.2.8.5.
Regional
Bifurcation
11.2.8.5.1.
North
America
11.2.8.5.1.1. Market Estimation, 2015 - 2021
11.2.8.5.1.2. Market Forecast, 2022 - 2030
11.2.8.5.2.
Europe
11.2.8.5.2.1. Market Estimation, 2015 - 2021
11.2.8.5.2.2. Market Forecast, 2022 - 2030
11.2.8.5.3.
Asia
Pacific
11.2.8.5.3.1. Market Estimation, 2015 - 2021
11.2.8.5.3.2. Market Forecast, 2022 - 2030
11.2.8.5.4.
Middle
East and Africa
11.2.8.5.4.1. Market Estimation, 2015 - 2021
11.2.8.5.4.2. Market Forecast, 2022 - 2030
11.2.8.5.5.
Latin
America
11.2.8.5.5.1. Market Estimation, 2015 - 2021
11.2.8.5.5.2. Market Forecast, 2022 - 2030
11.3. Key Segment for Channeling Investments
11.3.1. By Treatment
12. Global Multiple Sclerosis Market Analysis
and Forecasts, 2022 - 2030
12.1. Overview
12.2. Global Multiple Sclerosis Market Revenue (US$
Mn) and Forecasts, By End User
12.2.1. Hospitals and clinics
12.2.1.1.
Definition
12.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.1.3.
Market
Forecast, 2022 - 2030
12.2.1.4.
Compound
Annual Growth Rate (CAGR)
12.2.1.5.
Regional
Bifurcation
12.2.1.5.1.
North
America
12.2.1.5.1.1. Market Estimation, 2015 - 2021
12.2.1.5.1.2. Market Forecast, 2022 - 2030
12.2.1.5.2.
Europe
12.2.1.5.2.1. Market Estimation, 2015 - 2021
12.2.1.5.2.2. Market Forecast, 2022 - 2030
12.2.1.5.3.
Asia
Pacific
12.2.1.5.3.1. Market Estimation, 2015 - 2021
12.2.1.5.3.2. Market Forecast, 2022 - 2030
12.2.1.5.4.
Middle
East and Africa
12.2.1.5.4.1. Market Estimation, 2015 - 2021
12.2.1.5.4.2. Market Forecast, 2022 - 2030
12.2.1.5.5.
Latin
America
12.2.1.5.5.1. Market Estimation, 2015 - 2021
12.2.1.5.5.2. Market Forecast, 2022 - 2030
12.2.2. Specialty Clinics
12.2.2.1.
Definition
12.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.2.3.
Market
Forecast, 2022 - 2030
12.2.2.4.
Compound
Annual Growth Rate (CAGR)
12.2.2.5.
Regional
Bifurcation
12.2.2.5.1.
North
America
12.2.2.5.1.1. Market Estimation, 2015 - 2021
12.2.2.5.1.2. Market Forecast, 2022 - 2030
12.2.2.5.2.
Europe
12.2.2.5.2.1. Market Estimation, 2015 - 2021
12.2.2.5.2.2. Market Forecast, 2022 - 2030
12.2.2.5.3.
Asia
Pacific
12.2.2.5.3.1. Market Estimation, 2015 - 2021
12.2.2.5.3.2. Market Forecast, 2022 - 2030
12.2.2.5.4.
Middle
East and Africa
12.2.2.5.4.1. Market Estimation, 2015 - 2021
12.2.2.5.4.2. Market Forecast, 2022 - 2030
12.2.2.5.5.
Latin
America
12.2.2.5.5.1. Market Estimation, 2015 - 2021
12.2.2.5.5.2. Market Forecast, 2022 - 2030
12.2.3. Home Care
12.2.3.1.
Definition
12.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.3.3.
Market
Forecast, 2022 - 2030
12.2.3.4.
Compound
Annual Growth Rate (CAGR)
12.2.3.5.
Regional
Bifurcation
12.2.3.5.1.
North
America
12.2.3.5.1.1. Market Estimation, 2015 - 2021
12.2.3.5.1.2. Market Forecast, 2022 - 2030
12.2.3.5.2.
Europe
12.2.3.5.2.1. Market Estimation, 2015 - 2021
12.2.3.5.2.2. Market Forecast, 2022 - 2030
12.2.3.5.3.
Asia
Pacific
12.2.3.5.3.1. Market Estimation, 2015 - 2021
12.2.3.5.3.2. Market Forecast, 2022 - 2030
12.2.3.5.4.
Middle
East and Africa
12.2.3.5.4.1. Market Estimation, 2015 - 2021
12.2.3.5.4.2. Market Forecast, 2022 - 2030
12.2.3.5.5.
Latin
America
12.2.3.5.5.1. Market Estimation, 2015 - 2021
12.2.3.5.5.2. Market Forecast, 2022 - 2030
12.2.4. Others
12.2.4.1.
Definition
12.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.4.3.
Market
Forecast, 2022 - 2030
12.2.4.4.
Compound
Annual Growth Rate (CAGR)
12.2.4.5.
Regional
Bifurcation
12.2.4.5.1.
North
America
12.2.4.5.1.1. Market Estimation, 2015 - 2021
12.2.4.5.1.2. Market Forecast, 2022 - 2030
12.2.4.5.2.
Europe
12.2.4.5.2.1. Market Estimation, 2015 - 2021
12.2.4.5.2.2. Market Forecast, 2022 - 2030
12.2.4.5.3.
Asia
Pacific
12.2.4.5.3.1. Market Estimation, 2015 - 2021
12.2.4.5.3.2. Market Forecast, 2022 - 2030
12.2.4.5.4.
Middle
East and Africa
12.2.4.5.4.1. Market Estimation, 2015 - 2021
12.2.4.5.4.2. Market Forecast, 2022 - 2030
12.2.4.5.5.
Latin
America
12.2.4.5.5.1. Market Estimation, 2015 - 2021
12.2.4.5.5.2. Market Forecast, 2022 - 2030
12.3. Key Segment for Channeling Investments
12.3.1. By End User
13. North America Multiple Sclerosis Market
Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. North America Multiple Sclerosis Market
Revenue (US$ Mn)
13.2. North America Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Clinically isolated syndrome (CIS)
13.2.2. Relapse-remitting MS (RRMS)
13.2.3. Primary progressive MS (PPMS)
13.2.4. Secondary progressive MS (SPMS)
13.3. North America Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
13.3.1. Blood Test
13.3.2. Spinal Tap
13.3.3. MRI scans
13.3.4. Evoked potential tests
13.3.5. Optical coherence tomography (OCT)
13.3.6. Others
13.4. North America Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.4.1. Subcutaneous
13.4.2. Oral
13.4.3. Intravenous
13.5. North America Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By Treatment
13.5.1. Corticosteroids
13.5.2. Disease-modifying therapies (DMTs)
13.5.3. Plasma exchange (plasmapheresis)
13.5.4. Injectables
13.5.5. Oral Treatments
13.5.6. Infusions
13.5.7. Physical Therapy
13.5.8. Others
13.6. North America Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By End User
13.6.1. Hospitals and clinics
13.6.2. Specialty Clinics
13.6.3. Home Care
13.6.4. Others
13.7. North America Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By Country
13.7.1. U.S
13.7.1.1.
U.S
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
13.7.1.1.1.
Clinically
isolated syndrome (CIS)
13.7.1.1.2.
Relapse-remitting
MS (RRMS)
13.7.1.1.3.
Primary
progressive MS (PPMS)
13.7.1.1.4.
Secondary
progressive MS (SPMS)
13.7.1.2.
U.S
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.7.1.2.1.
Blood
Test
13.7.1.2.2.
Spinal
Tap
13.7.1.2.3.
MRI
scans
13.7.1.2.4.
Evoked
potential tests
13.7.1.2.5.
Optical
coherence tomography (OCT)
13.7.1.2.6.
Others
13.7.1.3.
U.S
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.7.1.3.1.
Subcutaneous
13.7.1.3.2.
Oral
13.7.1.3.3.
Intravenous
13.7.1.4.
U.S
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
13.7.1.4.1.
Corticosteroids
13.7.1.4.2.
Disease-modifying
therapies (DMTs)
13.7.1.4.3.
Plasma
exchange (plasmapheresis)
13.7.1.4.4.
Injectables
13.7.1.4.5.
Oral
Treatments
13.7.1.4.6.
Infusions
13.7.1.4.7.
Physical
Therapy
13.7.1.4.8.
Others
13.7.1.5.
U.S
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
13.7.1.5.1.
Hospitals
and clinics
13.7.1.5.2.
Specialty
Clinics
13.7.1.5.3.
Home
Care
13.7.1.5.4.
Others
13.7.2. Canada
13.7.2.1.
Canada
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
13.7.2.1.1.
Clinically
isolated syndrome (CIS)
13.7.2.1.2.
Relapse-remitting
MS (RRMS)
13.7.2.1.3.
Primary
progressive MS (PPMS)
13.7.2.1.4.
Secondary
progressive MS (SPMS)
13.7.2.2.
Canada
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.7.2.2.1.
Blood
Test
13.7.2.2.2.
Spinal
Tap
13.7.2.2.3.
MRI
scans
13.7.2.2.4.
Evoked
potential tests
13.7.2.2.5.
Optical
coherence tomography (OCT)
13.7.2.2.6.
Others
13.7.2.3.
Canada
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.7.2.3.1.
Subcutaneous
13.7.2.3.2.
Oral
13.7.2.3.3.
Intravenous
13.7.2.4.
Canada
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
13.7.2.4.1.
Corticosteroids
13.7.2.4.2.
Disease-modifying
therapies (DMTs)
13.7.2.4.3.
Plasma
exchange (plasmapheresis)
13.7.2.4.4.
Injectables
13.7.2.4.5.
Oral
Treatments
13.7.2.4.6.
Infusions
13.7.2.4.7.
Physical
Therapy
13.7.2.4.8.
Others
13.7.2.5.
Canada
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
13.7.2.5.1.
Hospitals
and clinics
13.7.2.5.2.
Specialty
Clinics
13.7.2.5.3.
Home
Care
13.7.2.5.4.
Others
13.7.3. Mexico
13.7.3.1.
Mexico
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
13.7.3.1.1.
Clinically
isolated syndrome (CIS)
13.7.3.1.2.
Relapse-remitting
MS (RRMS)
13.7.3.1.3.
Primary
progressive MS (PPMS)
13.7.3.1.4.
Secondary
progressive MS (SPMS)
13.7.3.2.
Mexico
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.7.3.2.1.
Blood
Test
13.7.3.2.2.
Spinal
Tap
13.7.3.2.3.
MRI
scans
13.7.3.2.4.
Evoked
potential tests
13.7.3.2.5.
Optical
coherence tomography (OCT)
13.7.3.2.6.
Others
13.7.3.3.
Mexico
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.7.3.3.1.
Subcutaneous
13.7.3.3.2.
Oral
13.7.3.3.3.
Intravenous
13.7.3.4.
Mexico
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
13.7.3.4.1.
Corticosteroids
13.7.3.4.2.
Disease-modifying
therapies (DMTs)
13.7.3.4.3.
Plasma
exchange (plasmapheresis)
13.7.3.4.4.
Injectables
13.7.3.4.5.
Oral
Treatments
13.7.3.4.6.
Infusions
13.7.3.4.7.
Physical
Therapy
13.7.3.4.8.
Others
13.7.3.5.
Mexico
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
13.7.3.5.1.
Hospitals
and clinics
13.7.3.5.2.
Specialty
Clinics
13.7.3.5.3.
Home
Care
13.7.3.5.4.
Others
13.7.4. Rest of North America
13.7.4.1.
Rest of
North America Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
13.7.4.1.1.
Clinically
isolated syndrome (CIS)
13.7.4.1.2.
Relapse-remitting
MS (RRMS)
13.7.4.1.3.
Primary
progressive MS (PPMS)
13.7.4.1.4.
Secondary
progressive MS (SPMS)
13.7.4.2.
Rest of
North America Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
13.7.4.2.1.
Blood
Test
13.7.4.2.2.
Spinal
Tap
13.7.4.2.3.
MRI
scans
13.7.4.2.4.
Evoked
potential tests
13.7.4.2.5.
Optical
coherence tomography (OCT)
13.7.4.2.6.
Others
13.7.4.3.
Rest of
North America Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
13.7.4.3.1.
Subcutaneous
13.7.4.3.2.
Oral
13.7.4.3.3.
Intravenous
13.7.4.4.
Rest of
North America Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By
Treatment
13.7.4.4.1.
Corticosteroids
13.7.4.4.2.
Disease-modifying
therapies (DMTs)
13.7.4.4.3.
Plasma
exchange (plasmapheresis)
13.7.4.4.4.
Injectables
13.7.4.4.5.
Oral
Treatments
13.7.4.4.6.
Infusions
13.7.4.4.7.
Physical
Therapy
13.7.4.4.8.
Others
13.7.4.5.
Rest of
North America Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End
User
13.7.4.5.1.
Hospitals
and clinics
13.7.4.5.2.
Specialty
Clinics
13.7.4.5.3.
Home
Care
13.7.4.5.4.
Others
13.8. Key Segment for Channeling Investments
13.8.1. By Country
13.8.2. By Type
13.8.3. By Diagnosis
13.8.4. By Route of Administration
13.8.5. By Treatment
13.8.6. By End User
14. Europe Multiple Sclerosis Market Analysis
and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Europe Multiple Sclerosis Market Revenue (US$
Mn)
14.2. Europe Multiple Sclerosis Market Revenue (US$
Mn) and Forecasts, By Type
14.2.1. Clinically isolated syndrome (CIS)
14.2.2. Relapse-remitting MS (RRMS)
14.2.3. Primary progressive MS (PPMS)
14.2.4. Secondary progressive MS (SPMS)
14.3. Europe Multiple Sclerosis Market Revenue (US$
Mn) and Forecasts, By Diagnosis
14.3.1. Blood Test
14.3.2. Spinal Tap
14.3.3. MRI scans
14.3.4. Evoked potential tests
14.3.5. Optical coherence tomography (OCT)
14.3.6. Others
14.4. Europe Multiple Sclerosis Market Revenue (US$
Mn) and Forecasts, By Route of Administration
14.4.1. Subcutaneous
14.4.2. Oral
14.4.3. Intravenous
14.5. Europe Multiple Sclerosis Market Revenue (US$
Mn) and Forecasts, By Treatment
14.5.1. Corticosteroids
14.5.2. Disease-modifying therapies (DMTs)
14.5.3. Plasma exchange (plasmapheresis)
14.5.4. Injectables
14.5.5. Oral Treatments
14.5.6. Infusions
14.5.7. Physical Therapy
14.5.8. Others
14.6. Europe Multiple Sclerosis Market Revenue (US$
Mn) and Forecasts, By End User
14.6.1. Hospitals and clinics
14.6.2. Specialty Clinics
14.6.3. Home Care
14.6.4. Others
14.7. Europe Multiple Sclerosis Market Revenue (US$
Mn) and Forecasts, By Country
14.7.1. France
14.7.1.1.
France
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
14.7.1.1.1.
Clinically
isolated syndrome (CIS)
14.7.1.1.2.
Relapse-remitting
MS (RRMS)
14.7.1.1.3.
Primary
progressive MS (PPMS)
14.7.1.1.4.
Secondary
progressive MS (SPMS)
14.7.1.2.
France
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.7.1.2.1.
Blood
Test
14.7.1.2.2.
Spinal
Tap
14.7.1.2.3.
MRI
scans
14.7.1.2.4.
Evoked potential
tests
14.7.1.2.5.
Optical
coherence tomography (OCT)
14.7.1.2.6.
Others
14.7.1.3.
France
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.1.3.1.
Subcutaneous
14.7.1.3.2.
Oral
14.7.1.3.3.
Intravenous
14.7.1.4.
France
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
14.7.1.4.1.
Corticosteroids
14.7.1.4.2.
Disease-modifying
therapies (DMTs)
14.7.1.4.3.
Plasma
exchange (plasmapheresis)
14.7.1.4.4.
Injectables
14.7.1.4.5.
Oral
Treatments
14.7.1.4.6.
Infusions
14.7.1.4.7.
Physical
Therapy
14.7.1.4.8.
Others
14.7.1.5.
France
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
14.7.1.5.1.
Hospitals
and clinics
14.7.1.5.2.
Specialty
Clinics
14.7.1.5.3.
Home
Care
14.7.1.5.4.
Others
14.7.2. The UK
14.7.2.1.
The UK
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
14.7.2.1.1.
Clinically
isolated syndrome (CIS)
14.7.2.1.2.
Relapse-remitting
MS (RRMS)
14.7.2.1.3.
Primary
progressive MS (PPMS)
14.7.2.1.4.
Secondary
progressive MS (SPMS)
14.7.2.2.
The UK
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.7.2.2.1.
Blood
Test
14.7.2.2.2.
Spinal
Tap
14.7.2.2.3.
MRI
scans
14.7.2.2.4.
Evoked
potential tests
14.7.2.2.5.
Optical
coherence tomography (OCT)
14.7.2.2.6.
Others
14.7.2.3.
The UK
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.2.3.1.
Subcutaneous
14.7.2.3.2.
Oral
14.7.2.3.3.
Intravenous
14.7.2.4.
The UK
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
14.7.2.4.1.
Corticosteroids
14.7.2.4.2.
Disease-modifying
therapies (DMTs)
14.7.2.4.3.
Plasma
exchange (plasmapheresis)
14.7.2.4.4.
Injectables
14.7.2.4.5.
Oral
Treatments
14.7.2.4.6.
Infusions
14.7.2.4.7.
Physical
Therapy
14.7.2.4.8.
Others
14.7.2.5.
The UK
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
14.7.2.5.1.
Hospitals
and clinics
14.7.2.5.2.
Specialty
Clinics
14.7.2.5.3.
Home
Care
14.7.2.5.4.
Others
14.7.3. Spain
14.7.3.1.
Spain
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
14.7.3.1.1.
Clinically
isolated syndrome (CIS)
14.7.3.1.2.
Relapse-remitting
MS (RRMS)
14.7.3.1.3.
Primary
progressive MS (PPMS)
14.7.3.1.4.
Secondary
progressive MS (SPMS)
14.7.3.2.
Spain
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.7.3.2.1.
Blood
Test
14.7.3.2.2.
Spinal
Tap
14.7.3.2.3.
MRI
scans
14.7.3.2.4.
Evoked
potential tests
14.7.3.2.5.
Optical
coherence tomography (OCT)
14.7.3.2.6.
Others
14.7.3.3.
Spain
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.3.3.1.
Subcutaneous
14.7.3.3.2.
Oral
14.7.3.3.3.
Intravenous
14.7.3.4.
Spain
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
14.7.3.4.1.
Corticosteroids
14.7.3.4.2.
Disease-modifying
therapies (DMTs)
14.7.3.4.3.
Plasma
exchange (plasmapheresis)
14.7.3.4.4.
Injectables
14.7.3.4.5.
Oral
Treatments
14.7.3.4.6.
Infusions
14.7.3.4.7.
Physical
Therapy
14.7.3.4.8.
Others
14.7.3.5.
Spain
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
14.7.3.5.1.
Hospitals
and clinics
14.7.3.5.2.
Specialty
Clinics
14.7.3.5.3.
Home
Care
14.7.3.5.4.
Others
14.7.4. Germany
14.7.4.1.
Germany
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
14.7.4.1.1.
Clinically
isolated syndrome (CIS)
14.7.4.1.2.
Relapse-remitting
MS (RRMS)
14.7.4.1.3.
Primary
progressive MS (PPMS)
14.7.4.1.4.
Secondary
progressive MS (SPMS)
14.7.4.2.
Germany
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.7.4.2.1.
Blood
Test
14.7.4.2.2.
Spinal
Tap
14.7.4.2.3.
MRI
scans
14.7.4.2.4.
Evoked
potential tests
14.7.4.2.5.
Optical
coherence tomography (OCT)
14.7.4.2.6.
Others
14.7.4.3.
Germany
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.4.3.1.
Subcutaneous
14.7.4.3.2.
Oral
14.7.4.3.3.
Intravenous
14.7.4.4.
Germany
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
14.7.4.4.1.
Corticosteroids
14.7.4.4.2.
Disease-modifying
therapies (DMTs)
14.7.4.4.3.
Plasma
exchange (plasmapheresis)
14.7.4.4.4.
Injectables
14.7.4.4.5.
Oral
Treatments
14.7.4.4.6.
Infusions
14.7.4.4.7.
Physical
Therapy
14.7.4.4.8.
Others
14.7.4.5.
Germany
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
14.7.4.5.1.
Hospitals
and clinics
14.7.4.5.2.
Specialty
Clinics
14.7.4.5.3.
Home
Care
14.7.4.5.4.
Others
14.7.5. Italy
14.7.5.1.
Italy
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
14.7.5.1.1.
Clinically
isolated syndrome (CIS)
14.7.5.1.2.
Relapse-remitting
MS (RRMS)
14.7.5.1.3.
Primary
progressive MS (PPMS)
14.7.5.1.4.
Secondary
progressive MS (SPMS)
14.7.5.2.
Italy
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.7.5.2.1.
Blood
Test
14.7.5.2.2.
Spinal
Tap
14.7.5.2.3.
MRI
scans
14.7.5.2.4.
Evoked
potential tests
14.7.5.2.5.
Optical
coherence tomography (OCT)
14.7.5.2.6.
Others
14.7.5.3.
Italy
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.5.3.1.
Subcutaneous
14.7.5.3.2.
Oral
14.7.5.3.3.
Intravenous
14.7.5.4.
Italy
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
14.7.5.4.1.
Corticosteroids
14.7.5.4.2.
Disease-modifying
therapies (DMTs)
14.7.5.4.3.
Plasma
exchange (plasmapheresis)
14.7.5.4.4.
Injectables
14.7.5.4.5.
Oral
Treatments
14.7.5.4.6.
Infusions
14.7.5.4.7.
Physical
Therapy
14.7.5.4.8.
Others
14.7.5.5.
Italy
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
14.7.5.5.1.
Hospitals
and clinics
14.7.5.5.2.
Specialty
Clinics
14.7.5.5.3.
Home
Care
14.7.5.5.4.
Others
14.7.6. Nordic Countries
14.7.6.1.
Nordic
Countries Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
14.7.6.1.1.
Clinically
isolated syndrome (CIS)
14.7.6.1.2.
Relapse-remitting
MS (RRMS)
14.7.6.1.3.
Primary
progressive MS (PPMS)
14.7.6.1.4.
Secondary
progressive MS (SPMS)
14.7.6.2.
Nordic
Countries Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
14.7.6.2.1.
Blood
Test
14.7.6.2.2.
Spinal
Tap
14.7.6.2.3.
MRI
scans
14.7.6.2.4.
Evoked
potential tests
14.7.6.2.5.
Optical
coherence tomography (OCT)
14.7.6.2.6.
Others
14.7.6.3.
Nordic
Countries Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.6.3.1.
Subcutaneous
14.7.6.3.2.
Oral
14.7.6.3.3.
Intravenous
14.7.6.4.
Nordic
Countries Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By
Treatment
14.7.6.4.1.
Corticosteroids
14.7.6.4.2.
Disease-modifying
therapies (DMTs)
14.7.6.4.3.
Plasma
exchange (plasmapheresis)
14.7.6.4.4.
Injectables
14.7.6.4.5.
Oral
Treatments
14.7.6.4.6.
Infusions
14.7.6.4.7.
Physical
Therapy
14.7.6.4.8.
Others
14.7.6.5.
Nordic
Countries Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
14.7.6.5.1.
Hospitals
and clinics
14.7.6.5.2.
Specialty
Clinics
14.7.6.5.3.
Home
Care
14.7.6.5.4.
Others
14.7.6.6.
Nordic
Countries Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Country
14.7.6.6.1.
Denmark
14.7.6.6.2.
Finland
14.7.6.6.3.
Iceland
14.7.6.6.4.
Sweden
14.7.6.6.5.
Norway
14.7.7. Benelux Union
14.7.7.1.
Benelux
Union Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
14.7.7.1.1.
Clinically
isolated syndrome (CIS)
14.7.7.1.2.
Relapse-remitting
MS (RRMS)
14.7.7.1.3.
Primary
progressive MS (PPMS)
14.7.7.1.4.
Secondary
progressive MS (SPMS)
14.7.7.2.
Benelux
Union Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.7.7.2.1.
Blood
Test
14.7.7.2.2.
Spinal
Tap
14.7.7.2.3.
MRI
scans
14.7.7.2.4.
Evoked
potential tests
14.7.7.2.5.
Optical
coherence tomography (OCT)
14.7.7.2.6.
Others
14.7.7.3.
Benelux
Union Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.7.3.1.
Subcutaneous
14.7.7.3.2.
Oral
14.7.7.3.3.
Intravenous
14.7.7.4.
Benelux
Union Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
14.7.7.4.1.
Corticosteroids
14.7.7.4.2.
Disease-modifying
therapies (DMTs)
14.7.7.4.3.
Plasma
exchange (plasmapheresis)
14.7.7.4.4.
Injectables
14.7.7.4.5.
Oral
Treatments
14.7.7.4.6.
Infusions
14.7.7.4.7.
Physical
Therapy
14.7.7.4.8.
Others
14.7.7.5.
Benelux
Union Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
14.7.7.5.1.
Hospitals
and clinics
14.7.7.5.2.
Specialty
Clinics
14.7.7.5.3.
Home
Care
14.7.7.5.4.
Others
14.7.7.6.
Benelux
Union Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Country
14.7.7.6.1.
Belgium
14.7.7.6.2.
The
Netherlands
14.7.7.6.3.
Luxembourg
14.7.8. Rest of Europe
14.7.8.1.
Rest of
Europe Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
14.7.8.1.1.
Clinically
isolated syndrome (CIS)
14.7.8.1.2.
Relapse-remitting
MS (RRMS)
14.7.8.1.3.
Primary
progressive MS (PPMS)
14.7.8.1.4.
Secondary
progressive MS (SPMS)
14.7.8.2.
Rest of
Europe Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.7.8.2.1.
Blood
Test
14.7.8.2.2.
Spinal
Tap
14.7.8.2.3.
MRI
scans
14.7.8.2.4.
Evoked
potential tests
14.7.8.2.5.
Optical
coherence tomography (OCT)
14.7.8.2.6.
Others
14.7.8.3.
Rest of
Europe Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.8.3.1.
Subcutaneous
14.7.8.3.2.
Oral
14.7.8.3.3.
Intravenous
14.7.8.4.
Rest of
Europe Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
14.7.8.4.1.
Corticosteroids
14.7.8.4.2.
Disease-modifying
therapies (DMTs)
14.7.8.4.3.
Plasma
exchange (plasmapheresis)
14.7.8.4.4.
Injectables
14.7.8.4.5.
Oral
Treatments
14.7.8.4.6.
Infusions
14.7.8.4.7.
Physical
Therapy
14.7.8.4.8.
Others
14.7.8.5.
Rest of
Europe Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
14.7.8.5.1.
Hospitals
and clinics
14.7.8.5.2.
Specialty
Clinics
14.7.8.5.3.
Home
Care
14.7.8.5.4.
Others
14.8. Key Segment for Channeling Investments
14.8.1. By Country
14.8.2. By Type
14.8.3. By Diagnosis
14.8.4. By Route of Administration
14.8.5. By Treatment
14.8.6. By End User
15. Asia Pacific Multiple Sclerosis Market
Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Asia Pacific Multiple Sclerosis Market
Revenue (US$ Mn)
15.2. Asia Pacific Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By Type
15.2.1. Clinically isolated syndrome (CIS)
15.2.2. Relapse-remitting MS (RRMS)
15.2.3. Primary progressive MS (PPMS)
15.2.4. Secondary progressive MS (SPMS)
15.3. Asia Pacific Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
15.3.1. Blood Test
15.3.2. Spinal Tap
15.3.3. MRI scans
15.3.4. Evoked potential tests
15.3.5. Optical coherence tomography (OCT)
15.3.6. Others
15.4. Asia Pacific Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.4.1. Subcutaneous
15.4.2. Oral
15.4.3. Intravenous
15.5. Asia Pacific Multiple Sclerosis Market Revenue
(US$ Mn) and Forecasts, By Treatment
15.5.1. Corticosteroids
15.5.2. Disease-modifying therapies (DMTs)
15.5.3. Plasma exchange (plasmapheresis)
15.5.4. Injectables
15.5.5. Oral Treatments
15.5.6. Infusions
15.5.7. Physical Therapy
15.5.8. Others
15.6. Asia Pacific Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By End User
15.6.1. Hospitals and clinics
15.6.2. Specialty Clinics
15.6.3. Home Care
15.6.4. Others
15.7. Asia Pacific Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By Country
15.7.1. China
15.7.1.1.
China
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
15.7.1.1.1.
Clinically
isolated syndrome (CIS)
15.7.1.1.2.
Relapse-remitting
MS (RRMS)
15.7.1.1.3.
Primary
progressive MS (PPMS)
15.7.1.1.4.
Secondary
progressive MS (SPMS)
15.7.1.2.
China
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.7.1.2.1.
Blood
Test
15.7.1.2.2.
Spinal
Tap
15.7.1.2.3.
MRI
scans
15.7.1.2.4.
Evoked
potential tests
15.7.1.2.5.
Optical coherence
tomography (OCT)
15.7.1.2.6.
Others
15.7.1.3.
China
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.1.3.1.
Subcutaneous
15.7.1.3.2.
Oral
15.7.1.3.3.
Intravenous
15.7.1.4.
China
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
15.7.1.4.1.
Corticosteroids
15.7.1.4.2.
Disease-modifying
therapies (DMTs)
15.7.1.4.3.
Plasma
exchange (plasmapheresis)
15.7.1.4.4.
Injectables
15.7.1.4.5.
Oral
Treatments
15.7.1.4.6.
Infusions
15.7.1.4.7.
Physical
Therapy
15.7.1.4.8.
Others
15.7.1.5.
China
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
15.7.1.5.1.
Hospitals
and clinics
15.7.1.5.2.
Specialty
Clinics
15.7.1.5.3.
Home Care
15.7.1.5.4.
Others
15.7.2. Japan
15.7.2.1.
Japan
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
15.7.2.1.1.
Clinically
isolated syndrome (CIS)
15.7.2.1.2.
Relapse-remitting
MS (RRMS)
15.7.2.1.3.
Primary
progressive MS (PPMS)
15.7.2.1.4.
Secondary
progressive MS (SPMS)
15.7.2.2.
Japan
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.7.2.2.1.
Blood
Test
15.7.2.2.2.
Spinal
Tap
15.7.2.2.3.
MRI
scans
15.7.2.2.4.
Evoked
potential tests
15.7.2.2.5.
Optical
coherence tomography (OCT)
15.7.2.2.6.
Others
15.7.2.3.
Japan
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.2.3.1.
Subcutaneous
15.7.2.3.2.
Oral
15.7.2.3.3.
Intravenous
15.7.2.4.
Japan
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
15.7.2.4.1.
Corticosteroids
15.7.2.4.2.
Disease-modifying
therapies (DMTs)
15.7.2.4.3.
Plasma
exchange (plasmapheresis)
15.7.2.4.4.
Injectables
15.7.2.4.5.
Oral
Treatments
15.7.2.4.6.
Infusions
15.7.2.4.7.
Physical
Therapy
15.7.2.4.8.
Others
15.7.2.5.
Japan
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
15.7.2.5.1.
Hospitals
and clinics
15.7.2.5.2.
Specialty
Clinics
15.7.2.5.3.
Home
Care
15.7.2.5.4.
Others
15.7.3. India
15.7.3.1.
India
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
15.7.3.1.1.
Clinically
isolated syndrome (CIS)
15.7.3.1.2.
Relapse-remitting
MS (RRMS)
15.7.3.1.3.
Primary
progressive MS (PPMS)
15.7.3.1.4.
Secondary
progressive MS (SPMS)
15.7.3.2.
India
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.7.3.2.1.
Blood
Test
15.7.3.2.2.
Spinal
Tap
15.7.3.2.3.
MRI
scans
15.7.3.2.4.
Evoked
potential tests
15.7.3.2.5.
Optical
coherence tomography (OCT)
15.7.3.2.6.
Others
15.7.3.3.
India Multiple
Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.3.3.1.
Subcutaneous
15.7.3.3.2.
Oral
15.7.3.3.3.
Intravenous
15.7.3.4.
India
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
15.7.3.4.1.
Corticosteroids
15.7.3.4.2.
Disease-modifying
therapies (DMTs)
15.7.3.4.3.
Plasma
exchange (plasmapheresis)
15.7.3.4.4.
Injectables
15.7.3.4.5.
Oral
Treatments
15.7.3.4.6.
Infusions
15.7.3.4.7.
Physical
Therapy
15.7.3.4.8.
Others
15.7.3.5.
India
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
15.7.3.5.1.
Hospitals
and clinics
15.7.3.5.2.
Specialty
Clinics
15.7.3.5.3.
Home
Care
15.7.3.5.4.
Others
15.7.4. New Zealand
15.7.4.1.
New
Zealand Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
15.7.4.1.1.
Clinically
isolated syndrome (CIS)
15.7.4.1.2.
Relapse-remitting
MS (RRMS)
15.7.4.1.3.
Primary
progressive MS (PPMS)
15.7.4.1.4.
Secondary
progressive MS (SPMS)
15.7.4.2.
New
Zealand Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.7.4.2.1.
Blood
Test
15.7.4.2.2.
Spinal
Tap
15.7.4.2.3.
MRI
scans
15.7.4.2.4.
Evoked
potential tests
15.7.4.2.5.
Optical
coherence tomography (OCT)
15.7.4.2.6.
Others
15.7.4.3.
New
Zealand Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.4.3.1.
Subcutaneous
15.7.4.3.2.
Oral
15.7.4.3.3.
Intravenous
15.7.4.4.
New
Zealand Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
15.7.4.4.1.
Corticosteroids
15.7.4.4.2.
Disease-modifying
therapies (DMTs)
15.7.4.4.3.
Plasma
exchange (plasmapheresis)
15.7.4.4.4.
Injectables
15.7.4.4.5.
Oral
Treatments
15.7.4.4.6.
Infusions
15.7.4.4.7.
Physical
Therapy
15.7.4.4.8.
Others
15.7.4.5.
New
Zealand Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
15.7.4.5.1.
Hospitals
and clinics
15.7.4.5.2.
Specialty
Clinics
15.7.4.5.3.
Home
Care
15.7.4.5.4.
Others
15.7.5. Australia
15.7.5.1.
Australia
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
15.7.5.1.1.
Clinically
isolated syndrome (CIS)
15.7.5.1.2.
Relapse-remitting
MS (RRMS)
15.7.5.1.3.
Primary
progressive MS (PPMS)
15.7.5.1.4.
Secondary
progressive MS (SPMS)
15.7.5.2.
Australia
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.7.5.2.1.
Blood
Test
15.7.5.2.2.
Spinal
Tap
15.7.5.2.3.
MRI
scans
15.7.5.2.4.
Evoked
potential tests
15.7.5.2.5.
Optical
coherence tomography (OCT)
15.7.5.2.6.
Others
15.7.5.3.
Australia
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.5.3.1.
Subcutaneous
15.7.5.3.2.
Oral
15.7.5.3.3.
Intravenous
15.7.5.4.
Australia
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
15.7.5.4.1.
Corticosteroids
15.7.5.4.2.
Disease-modifying
therapies (DMTs)
15.7.5.4.3.
Plasma
exchange (plasmapheresis)
15.7.5.4.4.
Injectables
15.7.5.4.5.
Oral
Treatments
15.7.5.4.6.
Infusions
15.7.5.4.7.
Physical
Therapy
15.7.5.4.8.
Others
15.7.5.5.
Australia
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
15.7.5.5.1.
Hospitals
and clinics
15.7.5.5.2.
Specialty
Clinics
15.7.5.5.3.
Home
Care
15.7.5.5.4.
Others
15.7.6. South Korea
15.7.6.1.
South
Korea Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
15.7.6.1.1.
Clinically
isolated syndrome (CIS)
15.7.6.1.2.
Relapse-remitting
MS (RRMS)
15.7.6.1.3.
Primary
progressive MS (PPMS)
15.7.6.1.4.
Secondary
progressive MS (SPMS)
15.7.6.2.
South
Korea Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.7.6.2.1.
Blood
Test
15.7.6.2.2.
Spinal
Tap
15.7.6.2.3.
MRI
scans
15.7.6.2.4.
Evoked
potential tests
15.7.6.2.5.
Optical
coherence tomography (OCT)
15.7.6.2.6.
Others
15.7.6.3.
South
Korea Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.6.3.1.
Subcutaneous
15.7.6.3.2.
Oral
15.7.6.3.3.
Intravenous
15.7.6.4.
South
Korea Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
15.7.6.4.1.
Corticosteroids
15.7.6.4.2.
Disease-modifying
therapies (DMTs)
15.7.6.4.3.
Plasma
exchange (plasmapheresis)
15.7.6.4.4.
Injectables
15.7.6.4.5.
Oral
Treatments
15.7.6.4.6.
Infusions
15.7.6.4.7.
Physical
Therapy
15.7.6.4.8.
Others
15.7.6.5.
South
Korea Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
15.7.6.5.1.
Hospitals
and clinics
15.7.6.5.2.
Specialty
Clinics
15.7.6.5.3.
Home
Care
15.7.6.5.4.
Others
15.7.7. Southeast Asia
15.7.7.1.
Southeast
Asia Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
15.7.7.1.1.
Clinically
isolated syndrome (CIS)
15.7.7.1.2.
Relapse-remitting
MS (RRMS)
15.7.7.1.3.
Primary
progressive MS (PPMS)
15.7.7.1.4.
Secondary
progressive MS (SPMS)
15.7.7.2.
Southeast
Asia Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.7.7.2.1.
Blood
Test
15.7.7.2.2.
Spinal
Tap
15.7.7.2.3.
MRI
scans
15.7.7.2.4.
Evoked
potential tests
15.7.7.2.5.
Optical
coherence tomography (OCT)
15.7.7.2.6.
Others
15.7.7.3.
Southeast
Asia Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.7.3.1.
Subcutaneous
15.7.7.3.2.
Oral
15.7.7.3.3.
Intravenous
15.7.7.4.
Southeast
Asia Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
15.7.7.4.1.
Corticosteroids
15.7.7.4.2.
Disease-modifying
therapies (DMTs)
15.7.7.4.3.
Plasma
exchange (plasmapheresis)
15.7.7.4.4.
Injectables
15.7.7.4.5.
Oral
Treatments
15.7.7.4.6.
Infusions
15.7.7.4.7.
Physical
Therapy
15.7.7.4.8.
Others
15.7.7.5.
Southeast
Asia Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
15.7.7.5.1.
Hospitals
and clinics
15.7.7.5.2.
Specialty
Clinics
15.7.7.5.3.
Home
Care
15.7.7.5.4.
Others
15.7.7.6.
Southeast
Asia Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Country
15.7.7.6.1.
Indonesia
15.7.7.6.2.
Thailand
15.7.7.6.3.
Malaysia
15.7.7.6.4.
Singapore
15.7.7.6.5.
Rest of
Southeast Asia
15.7.8. Rest of Asia Pacific
15.7.8.1.
Rest of
Asia Pacific Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
15.7.8.1.1.
Clinically
isolated syndrome (CIS)
15.7.8.1.2.
Relapse-remitting
MS (RRMS)
15.7.8.1.3.
Primary
progressive MS (PPMS)
15.7.8.1.4.
Secondary
progressive MS (SPMS)
15.7.8.2.
Rest of
Asia Pacific Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
15.7.8.2.1.
Blood
Test
15.7.8.2.2.
Spinal
Tap
15.7.8.2.3.
MRI
scans
15.7.8.2.4.
Evoked
potential tests
15.7.8.2.5.
Optical
coherence tomography (OCT)
15.7.8.2.6.
Others
15.7.8.3.
Rest of
Asia Pacific Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.7.8.3.1.
Subcutaneous
15.7.8.3.2.
Oral
15.7.8.3.3.
Intravenous
15.7.8.4.
Rest of
Asia Pacific Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By
Treatment
15.7.8.4.1.
Corticosteroids
15.7.8.4.2.
Disease-modifying
therapies (DMTs)
15.7.8.4.3.
Plasma
exchange (plasmapheresis)
15.7.8.4.4.
Injectables
15.7.8.4.5.
Oral
Treatments
15.7.8.4.6.
Infusions
15.7.8.4.7.
Physical
Therapy
15.7.8.4.8.
Others
15.7.8.5.
Rest of
Asia Pacific Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End
User
15.7.8.5.1.
Hospitals
and clinics
15.7.8.5.2.
Specialty
Clinics
15.7.8.5.3.
Home
Care
15.7.8.5.4.
Others
15.8. Key Segment for Channeling Investments
15.8.1. By Country
15.8.2. By Type
15.8.3. By Diagnosis
15.8.4. By Route of Administration
15.8.5. By Treatment
15.8.6. By End User
16. Middle East and Africa Multiple Sclerosis
Market Analysis and Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Middle East and Africa Multiple Sclerosis
Market Revenue (US$ Mn)
16.2. Middle East and Africa Multiple Sclerosis
Market Revenue (US$ Mn) and Forecasts, By Type
16.2.1. Clinically isolated syndrome (CIS)
16.2.2. Relapse-remitting MS (RRMS)
16.2.3. Primary progressive MS (PPMS)
16.2.4. Secondary progressive MS (SPMS)
16.3. Middle East and Africa Multiple Sclerosis
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
16.3.1. Blood Test
16.3.2. Spinal Tap
16.3.3. MRI scans
16.3.4. Evoked potential tests
16.3.5. Optical coherence tomography (OCT)
16.3.6. Others
16.4. Middle East and Africa Multiple Sclerosis
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.4.1. Subcutaneous
16.4.2. Oral
16.4.3. Intravenous
16.5. Middle East and Africa Multiple Sclerosis
Market Revenue (US$ Mn) and Forecasts, By Treatment
16.5.1. Corticosteroids
16.5.2. Disease-modifying therapies (DMTs)
16.5.3. Plasma exchange (plasmapheresis)
16.5.4. Injectables
16.5.5. Oral Treatments
16.5.6. Infusions
16.5.7. Physical Therapy
16.5.8. Others
16.6. Middle East and Africa Multiple Sclerosis
Market Revenue (US$ Mn) and Forecasts, By End User
16.6.1. Hospitals and clinics
16.6.2. Specialty Clinics
16.6.3. Home Care
16.6.4. Others
16.7. Middle East and Africa Multiple Sclerosis
Market Revenue (US$ Mn) and Forecasts, By Country
16.7.1. Saudi Arabia
16.7.1.1.
Saudi
Arabia Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
16.7.1.1.1.
Clinically
isolated syndrome (CIS)
16.7.1.1.2.
Relapse-remitting
MS (RRMS)
16.7.1.1.3.
Primary
progressive MS (PPMS)
16.7.1.1.4.
Secondary
progressive MS (SPMS)
16.7.1.2.
Saudi
Arabia Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
16.7.1.2.1.
Blood
Test
16.7.1.2.2.
Spinal
Tap
16.7.1.2.3.
MRI
scans
16.7.1.2.4.
Evoked
potential tests
16.7.1.2.5.
Optical
coherence tomography (OCT)
16.7.1.2.6.
Others
16.7.1.3.
Saudi
Arabia Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.1.3.1.
Subcutaneous
16.7.1.3.2.
Oral
16.7.1.3.3.
Intravenous
16.7.1.4.
Saudi
Arabia Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
16.7.1.4.1.
Corticosteroids
16.7.1.4.2.
Disease-modifying
therapies (DMTs)
16.7.1.4.3.
Plasma
exchange (plasmapheresis)
16.7.1.4.4.
Injectables
16.7.1.4.5.
Oral
Treatments
16.7.1.4.6.
Infusions
16.7.1.4.7.
Physical
Therapy
16.7.1.4.8.
Others
16.7.1.5.
Saudi
Arabia Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
16.7.1.5.1.
Hospitals
and clinics
16.7.1.5.2.
Specialty
Clinics
16.7.1.5.3.
Home
Care
16.7.1.5.4.
Others
16.7.2. UAE
16.7.2.1.
UAE
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
16.7.2.1.1.
Clinically
isolated syndrome (CIS)
16.7.2.1.2.
Relapse-remitting
MS (RRMS)
16.7.2.1.3.
Primary
progressive MS (PPMS)
16.7.2.1.4.
Secondary
progressive MS (SPMS)
16.7.2.2.
UAE
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
16.7.2.2.1.
Blood
Test
16.7.2.2.2.
Spinal
Tap
16.7.2.2.3.
MRI
scans
16.7.2.2.4.
Evoked
potential tests
16.7.2.2.5.
Optical
coherence tomography (OCT)
16.7.2.2.6.
Others
16.7.2.3.
UAE
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.2.3.1.
Subcutaneous
16.7.2.3.2.
Oral
16.7.2.3.3.
Intravenous
16.7.2.4.
UAE
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
16.7.2.4.1.
Corticosteroids
16.7.2.4.2.
Disease-modifying
therapies (DMTs)
16.7.2.4.3.
Plasma
exchange (plasmapheresis)
16.7.2.4.4.
Injectables
16.7.2.4.5.
Oral
Treatments
16.7.2.4.6.
Infusions
16.7.2.4.7.
Physical
Therapy
16.7.2.4.8.
Others
16.7.2.5.
UAE
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
16.7.2.5.1.
Hospitals
and clinics
16.7.2.5.2.
Specialty
Clinics
16.7.2.5.3.
Home
Care
16.7.2.5.4.
Others
16.7.3. Egypt
16.7.3.1.
Egypt
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
16.7.3.1.1.
Clinically
isolated syndrome (CIS)
16.7.3.1.2.
Relapse-remitting
MS (RRMS)
16.7.3.1.3.
Primary
progressive MS (PPMS)
16.7.3.1.4.
Secondary
progressive MS (SPMS)
16.7.3.2.
Egypt
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
16.7.3.2.1.
Blood
Test
16.7.3.2.2.
Spinal
Tap
16.7.3.2.3.
MRI
scans
16.7.3.2.4.
Evoked
potential tests
16.7.3.2.5.
Optical
coherence tomography (OCT)
16.7.3.2.6.
Others
16.7.3.3.
Egypt
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.3.3.1.
Subcutaneous
16.7.3.3.2.
Oral
16.7.3.3.3.
Intravenous
16.7.3.4.
Egypt
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
16.7.3.4.1.
Corticosteroids
16.7.3.4.2.
Disease-modifying
therapies (DMTs)
16.7.3.4.3.
Plasma
exchange (plasmapheresis)
16.7.3.4.4.
Injectables
16.7.3.4.5.
Oral
Treatments
16.7.3.4.6.
Infusions
16.7.3.4.7.
Physical
Therapy
16.7.3.4.8.
Others
16.7.3.5.
Egypt
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
16.7.3.5.1.
Hospitals
and clinics
16.7.3.5.2.
Specialty
Clinics
16.7.3.5.3.
Home
Care
16.7.3.5.4.
Others
16.7.4. Kuwait
16.7.4.1.
Kuwait
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
16.7.4.1.1.
Clinically
isolated syndrome (CIS)
16.7.4.1.2.
Relapse-remitting
MS (RRMS)
16.7.4.1.3.
Primary
progressive MS (PPMS)
16.7.4.1.4.
Secondary
progressive MS (SPMS)
16.7.4.2.
Kuwait
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
16.7.4.2.1.
Blood
Test
16.7.4.2.2.
Spinal
Tap
16.7.4.2.3.
MRI
scans
16.7.4.2.4.
Evoked
potential tests
16.7.4.2.5.
Optical
coherence tomography (OCT)
16.7.4.2.6.
Others
16.7.4.3.
Kuwait
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.4.3.1.
Subcutaneous
16.7.4.3.2.
Oral
16.7.4.3.3.
Intravenous
16.7.4.4.
Kuwait
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
16.7.4.4.1.
Corticosteroids
16.7.4.4.2.
Disease-modifying
therapies (DMTs)
16.7.4.4.3.
Plasma
exchange (plasmapheresis)
16.7.4.4.4.
Injectables
16.7.4.4.5.
Oral
Treatments
16.7.4.4.6.
Infusions
16.7.4.4.7.
Physical
Therapy
16.7.4.4.8.
Others
16.7.4.5.
Kuwait
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
16.7.4.5.1.
Hospitals
and clinics
16.7.4.5.2.
Specialty
Clinics
16.7.4.5.3.
Home
Care
16.7.4.5.4.
Others
16.7.5. South Africa
16.7.5.1.
South
Africa Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
16.7.5.1.1.
Clinically
isolated syndrome (CIS)
16.7.5.1.2.
Relapse-remitting
MS (RRMS)
16.7.5.1.3.
Primary
progressive MS (PPMS)
16.7.5.1.4.
Secondary
progressive MS (SPMS)
16.7.5.2.
South
Africa Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
16.7.5.2.1.
Blood
Test
16.7.5.2.2.
Spinal
Tap
16.7.5.2.3.
MRI
scans
16.7.5.2.4.
Evoked
potential tests
16.7.5.2.5.
Optical
coherence tomography (OCT)
16.7.5.2.6.
Others
16.7.5.3.
South
Africa Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.5.3.1.
Subcutaneous
16.7.5.3.2.
Oral
16.7.5.3.3.
Intravenous
16.7.5.4.
South
Africa Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
16.7.5.4.1.
Corticosteroids
16.7.5.4.2.
Disease-modifying
therapies (DMTs)
16.7.5.4.3.
Plasma
exchange (plasmapheresis)
16.7.5.4.4.
Injectables
16.7.5.4.5.
Oral
Treatments
16.7.5.4.6.
Infusions
16.7.5.4.7.
Physical
Therapy
16.7.5.4.8.
Others
16.7.5.5.
South Africa
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
16.7.5.5.1.
Hospitals
and clinics
16.7.5.5.2.
Specialty
Clinics
16.7.5.5.3.
Home
Care
16.7.5.5.4.
Others
16.7.6. Rest of Middle East & Africa
16.7.6.1.
Rest of
Middle East & Africa Multiple Sclerosis Market Revenue (US$ Mn) and
Forecasts, By Type
16.7.6.1.1.
Clinically
isolated syndrome (CIS)
16.7.6.1.2.
Relapse-remitting
MS (RRMS)
16.7.6.1.3.
Primary
progressive MS (PPMS)
16.7.6.1.4.
Secondary
progressive MS (SPMS)
16.7.6.2.
Rest of
Middle East & Africa Multiple Sclerosis Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
16.7.6.2.1.
Blood
Test
16.7.6.2.2.
Spinal
Tap
16.7.6.2.3.
MRI scans
16.7.6.2.4.
Evoked
potential tests
16.7.6.2.5.
Optical
coherence tomography (OCT)
16.7.6.2.6.
Others
16.7.6.3.
Rest of
Middle East & Africa Multiple Sclerosis Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.7.6.3.1.
Subcutaneous
16.7.6.3.2.
Oral
16.7.6.3.3.
Intravenous
16.7.6.4.
Rest of
Middle East & Africa Multiple Sclerosis Market Revenue (US$ Mn) and
Forecasts, By Treatment
16.7.6.4.1.
Corticosteroids
16.7.6.4.2.
Disease-modifying
therapies (DMTs)
16.7.6.4.3.
Plasma
exchange (plasmapheresis)
16.7.6.4.4.
Injectables
16.7.6.4.5.
Oral
Treatments
16.7.6.4.6.
Infusions
16.7.6.4.7.
Physical
Therapy
16.7.6.4.8.
Others
16.7.6.5.
Rest of
Middle East & Africa Multiple Sclerosis Market Revenue (US$ Mn) and
Forecasts, By End User
16.7.6.5.1.
Hospitals
and clinics
16.7.6.5.2.
Specialty
Clinics
16.7.6.5.3.
Home
Care
16.7.6.5.4.
Others
16.8. Key Segment for Channeling Investments
16.8.1. By Country
16.8.2. By Type
16.8.3. By Diagnosis
16.8.4. By Route of Administration
16.8.5. By Treatment
16.8.6. By End User
17. Latin America Multiple Sclerosis Market
Analysis and Forecasts, 2022 - 2030
17.1. Overview
17.1.1. Latin America Multiple Sclerosis Market
Revenue (US$ Mn)
17.2. Latin America Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By Type
17.2.1. Clinically isolated syndrome (CIS)
17.2.2. Relapse-remitting MS (RRMS)
17.2.3. Primary progressive MS (PPMS)
17.2.4. Secondary progressive MS (SPMS)
17.3. Latin America Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
17.3.1. Blood Test
17.3.2. Spinal Tap
17.3.3. MRI scans
17.3.4. Evoked potential tests
17.3.5. Optical coherence tomography (OCT)
17.3.6. Others
17.4. Latin America Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
17.4.1. Subcutaneous
17.4.2. Oral
17.4.3. Intravenous
17.5. Latin America Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By Treatment
17.5.1. Corticosteroids
17.5.2. Disease-modifying therapies (DMTs)
17.5.3. Plasma exchange (plasmapheresis)
17.5.4. Injectables
17.5.5. Oral Treatments
17.5.6. Infusions
17.5.7. Physical Therapy
17.5.8. Others
17.6. Latin America Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By End User
17.6.1. Hospitals and clinics
17.6.2. Specialty Clinics
17.6.3. Home Care
17.6.4. Others
17.7. Latin America Multiple Sclerosis Market
Revenue (US$ Mn) and Forecasts, By Country
17.7.1. Brazil
17.7.1.1.
Brazil
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
17.7.1.1.1.
Clinically
isolated syndrome (CIS)
17.7.1.1.2.
Relapse-remitting
MS (RRMS)
17.7.1.1.3.
Primary
progressive MS (PPMS)
17.7.1.1.4.
Secondary
progressive MS (SPMS)
17.7.1.2.
Brazil
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
17.7.1.2.1.
Blood
Test
17.7.1.2.2.
Spinal
Tap
17.7.1.2.3.
MRI
scans
17.7.1.2.4.
Evoked
potential tests
17.7.1.2.5.
Optical
coherence tomography (OCT)
17.7.1.2.6.
Others
17.7.1.3.
Brazil
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
17.7.1.3.1.
Subcutaneous
17.7.1.3.2.
Oral
17.7.1.3.3.
Intravenous
17.7.1.4.
Brazil
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
17.7.1.4.1.
Corticosteroids
17.7.1.4.2.
Disease-modifying
therapies (DMTs)
17.7.1.4.3.
Plasma
exchange (plasmapheresis)
17.7.1.4.4.
Injectables
17.7.1.4.5.
Oral
Treatments
17.7.1.4.6.
Infusions
17.7.1.4.7.
Physical
Therapy
17.7.1.4.8.
Others
17.7.1.5.
Brazil
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
17.7.1.5.1.
Hospitals
and clinics
17.7.1.5.2.
Specialty
Clinics
17.7.1.5.3.
Home
Care
17.7.1.5.4.
Others
17.7.2. Argentina
17.7.2.1.
Argentina
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
17.7.2.1.1.
Clinically
isolated syndrome (CIS)
17.7.2.1.2.
Relapse-remitting
MS (RRMS)
17.7.2.1.3.
Primary
progressive MS (PPMS)
17.7.2.1.4.
Secondary
progressive MS (SPMS)
17.7.2.2.
Argentina
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Diagnosis
17.7.2.2.1.
Blood
Test
17.7.2.2.2.
Spinal
Tap
17.7.2.2.3.
MRI
scans
17.7.2.2.4.
Evoked
potential tests
17.7.2.2.5.
Optical
coherence tomography (OCT)
17.7.2.2.6.
Others
17.7.2.3.
Argentina
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
17.7.2.3.1.
Subcutaneous
17.7.2.3.2.
Oral
17.7.2.3.3.
Intravenous
17.7.2.4.
Argentina
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Treatment
17.7.2.4.1.
Corticosteroids
17.7.2.4.2.
Disease-modifying
therapies (DMTs)
17.7.2.4.3.
Plasma
exchange (plasmapheresis)
17.7.2.4.4.
Injectables
17.7.2.4.5.
Oral
Treatments
17.7.2.4.6.
Infusions
17.7.2.4.7.
Physical
Therapy
17.7.2.4.8.
Others
17.7.2.5.
Argentina
Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End User
17.7.2.5.1.
Hospitals
and clinics
17.7.2.5.2.
Specialty
Clinics
17.7.2.5.3.
Home
Care
17.7.2.5.4.
Others
17.7.3. Rest of Latin America
17.7.3.1.
Rest of
Latin America Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By Type
17.7.3.1.1.
Clinically
isolated syndrome (CIS)
17.7.3.1.2.
Relapse-remitting
MS (RRMS)
17.7.3.1.3.
Primary
progressive MS (PPMS)
17.7.3.1.4.
Secondary
progressive MS (SPMS)
17.7.3.2.
Rest of
Latin America Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
17.7.3.2.1.
Blood
Test
17.7.3.2.2.
Spinal
Tap
17.7.3.2.3.
MRI
scans
17.7.3.2.4.
Evoked
potential tests
17.7.3.2.5.
Optical
coherence tomography (OCT)
17.7.3.2.6.
Others
17.7.3.3.
Rest of
Latin America Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
17.7.3.3.1.
Subcutaneous
17.7.3.3.2.
Oral
17.7.3.3.3.
Intravenous
17.7.3.4.
Rest of
Latin America Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By
Treatment
17.7.3.4.1.
Corticosteroids
17.7.3.4.2.
Disease-modifying
therapies (DMTs)
17.7.3.4.3.
Plasma
exchange (plasmapheresis)
17.7.3.4.4.
Injectables
17.7.3.4.5.
Oral
Treatments
17.7.3.4.6.
Infusions
17.7.3.4.7.
Physical
Therapy
17.7.3.4.8.
Others
17.7.3.5.
Rest of
Latin America Multiple Sclerosis Market Revenue (US$ Mn) and Forecasts, By End
User
17.7.3.5.1.
Hospitals
and clinics
17.7.3.5.2.
Specialty
Clinics
17.7.3.5.3.
Home
Care
17.7.3.5.4.
Others
17.8. Key Segment for Channeling Investments
17.8.1. By Country
17.8.2. By Type
17.8.3. By Diagnosis
17.8.4. By Route of Administration
17.8.5. By Treatment
17.8.6. By End User
18. Competitive Benchmarking
18.1. Brand Benchmarking
18.2. Market Share Analysis, 2021
18.3. Global Presence and Growth Strategies
18.3.1. Mergers and Acquisitions
18.3.2. Product Launches
18.3.3. Investments Trends
18.3.4. R&D Initiatives
19. Player Profiles
19.1. Acorda Therapeutics
19.1.1. Company Details
19.1.2. Company Overview
19.1.3. Product Offerings
19.1.4. Key Developments
19.1.5. Financial Analysis
19.1.6. SWOT Analysis
19.1.7. Business Strategies
19.2. Bayer AG
19.2.1. Company Details
19.2.2. Company Overview
19.2.3. Product Offerings
19.2.4. Key Developments
19.2.5. Financial Analysis
19.2.6. SWOT Analysis
19.2.7. Business Strategies
19.3. BerlexÂ
19.3.1. Company Details
19.3.2. Company Overview
19.3.3. Product Offerings
19.3.4. Key Developments
19.3.5. Financial Analysis
19.3.6. SWOT Analysis
19.3.7. Business Strategies
19.4. Biogen
19.4.1. Company Details
19.4.2. Company Overview
19.4.3. Product Offerings
19.4.4. Key Developments
19.4.5. Financial Analysis
19.4.6. SWOT Analysis
19.4.7. Business Strategies
19.5. F. Hoffmann-La Roche Ltd
19.5.1. Company Details
19.5.2. Company Overview
19.5.3. Product Offerings
19.5.4. Key Developments
19.5.5. Financial Analysis
19.5.6. SWOT Analysis
19.5.7. Business Strategies
19.6. Novartis AG
19.6.1. Company Details
19.6.2. Company Overview
19.6.3. Product Offerings
19.6.4. Key Developments
19.6.5. Financial Analysis
19.6.6. SWOT Analysis
19.6.7. Business Strategies
19.7. Pfizer Inc
19.7.1. Company Details
19.7.2. Company Overview
19.7.3. Product Offerings
19.7.4. Key Developments
19.7.5. Financial Analysis
19.7.6. SWOT Analysis
19.7.7. Business Strategies
19.8. Sanofi
19.8.1. Company Details
19.8.2. Company Overview
19.8.3. Product Offerings
19.8.4. Key Developments
19.8.5. Financial Analysis
19.8.6. SWOT Analysis
19.8.7. Business Strategies
19.9. Teva Pharmaceutical Industries Ltd.
19.9.1. Company Details
19.9.2. Company Overview
19.9.3. Product Offerings
19.9.4. Key Developments
19.9.5. Financial Analysis
19.9.6. SWOT Analysis
19.9.7. Business Strategies
19.10. TG Therapeutics, Inc.
19.10.1. Company Details
19.10.2. Company Overview
19.10.3. Product Offerings
19.10.4. Key Developments
19.10.5. Financial Analysis
19.10.6. SWOT Analysis
19.10.7. Business Strategies
19.11. Other Market Participants
20. Key Findings
Note: This ToC is tentative and
can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.